[go: up one dir, main page]

DK0810880T3 - Præparater og assays, hvor der anvendes subunits af enzymer - Google Patents

Præparater og assays, hvor der anvendes subunits af enzymer

Info

Publication number
DK0810880T3
DK0810880T3 DK96903111T DK96903111T DK0810880T3 DK 0810880 T3 DK0810880 T3 DK 0810880T3 DK 96903111 T DK96903111 T DK 96903111T DK 96903111 T DK96903111 T DK 96903111T DK 0810880 T3 DK0810880 T3 DK 0810880T3
Authority
DK
Denmark
Prior art keywords
agent
constituted
components
subunits
assays
Prior art date
Application number
DK96903111T
Other languages
English (en)
Inventor
Richard William Titball
Francis Joseph Carr
Original Assignee
Biovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovation Ltd filed Critical Biovation Ltd
Application granted granted Critical
Publication of DK0810880T3 publication Critical patent/DK0810880T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/81Packaged device or kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906Drug delivery
    • Y10S977/907Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK96903111T 1995-02-22 1996-02-21 Præparater og assays, hvor der anvendes subunits af enzymer DK0810880T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9503486.4A GB9503486D0 (en) 1995-02-22 1995-02-22 Pharmaceuticals and assays using enzyme subunits
PCT/GB1996/000380 WO1996025952A1 (en) 1995-02-22 1996-02-21 Pharmaceuticals and assays using enzyme subunits

Publications (1)

Publication Number Publication Date
DK0810880T3 true DK0810880T3 (da) 2003-01-06

Family

ID=10770034

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96903111T DK0810880T3 (da) 1995-02-22 1996-02-21 Præparater og assays, hvor der anvendes subunits af enzymer

Country Status (15)

Country Link
US (2) US6472365B1 (da)
EP (1) EP0810880B1 (da)
JP (1) JPH11500136A (da)
KR (1) KR19980702499A (da)
CN (1) CN1188704C (da)
AT (1) ATE224204T1 (da)
AU (1) AU714396B2 (da)
CA (1) CA2213566A1 (da)
DE (1) DE69623755T2 (da)
DK (1) DK0810880T3 (da)
ES (1) ES2182962T3 (da)
GB (1) GB9503486D0 (da)
PT (1) PT810880E (da)
WO (1) WO1996025952A1 (da)
ZA (1) ZA961427B (da)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4463090A (en) * 1981-09-30 1984-07-31 Harris Curtis C Cascade amplification enzyme immunoassay
US4900556A (en) 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
GB8528761D0 (en) * 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies
US4874710A (en) * 1986-02-20 1989-10-17 Becton Dickinson And Company Assay and product in which binder and liposomes are supported on a solid support
EP0301333A3 (en) 1987-07-29 1992-07-01 Abbott Laboratories Liposome based homogeneous immunoassay for diagnostic tests
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
JPH04200632A (ja) 1990-11-29 1992-07-21 Toyo Ink Mfg Co Ltd リポソームの破壊方法
JPH0556797A (ja) 1991-08-31 1993-03-09 Toyo Ink Mfg Co Ltd リポソーム破壊物質の検出方法
US5277913A (en) * 1991-09-09 1994-01-11 Thompson David H Liposomal delivery system with photoactivatable triggered release
DE69407292T2 (de) * 1993-06-30 1998-06-25 Genentech Inc Verfahren zur herstellung von liposomen

Also Published As

Publication number Publication date
DE69623755D1 (de) 2002-10-24
US20020035084A1 (en) 2002-03-21
WO1996025952A1 (en) 1996-08-29
ES2182962T3 (es) 2003-03-16
CA2213566A1 (en) 1996-08-29
JPH11500136A (ja) 1999-01-06
AU4725996A (en) 1996-09-11
EP0810880B1 (en) 2002-09-18
EP0810880A1 (en) 1997-12-10
ZA961427B (en) 1996-08-07
PT810880E (pt) 2003-02-28
US6472365B1 (en) 2002-10-29
ATE224204T1 (de) 2002-10-15
GB9503486D0 (en) 1995-04-12
AU714396B2 (en) 2000-01-06
DE69623755T2 (de) 2003-06-05
US6974699B2 (en) 2005-12-13
KR19980702499A (ko) 1998-07-15
CN1188704C (zh) 2005-02-09
CN1182372A (zh) 1998-05-20

Similar Documents

Publication Publication Date Title
Bade et al. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates
BR9713521A (da)
ES2171705T3 (es) Complejos de polipeptido-dendrimero.
DE69407402D1 (de) Repamycinbestimmung
Mary et al. Posttranslational Modifications in the C-terminal Tail of Axonemal Tubulin from Sea Urchin Sperm (∗)
DK261386A (da) Monoklonale antistoffer
WEIR et al. Destruction of endogenous peroxidase activity in order to locate cellular antigens by peroxidase-labeled antibodies
DE60044420D1 (de) Enzym-Protein-Komplex
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
Rascón et al. Purification and properties of the cGMP-inhibited cAMP phosphodiesterase from bovine aortic smooth muscle
ES2136598T3 (es) Inmunoanalisis de deteccion de anticuerpos monoclonales contra los peptidos de activacion de protrombina y sus productos de degradacion.
DK0810880T3 (da) Præparater og assays, hvor der anvendes subunits af enzymer
Enjyoji et al. Purification and characterization of rat T-kininogens isolated from plasma of adjuvant-treated rats. Identification of three kinds of T-kininogens.
Shime et al. Association of Pasteurella multocida toxin with vimentin
Choumet et al. Production of an immunoenzymatic tracer combining a scFv and the acetylcholinesterase of Bungarus fasciatus by genetic recombination
Primiano et al. Enhanced expression, purification, and characterization of a novel class α glutathione S-transferase isozyme appearing in rabbit hepatic cytosol following treatment with 4-picoline
ES2060146T3 (es) Metaloproteinasas colagenoliticas asociadas con metastasis.
CO5300499A1 (es) Ensayo de inmunoabsorbente ligado a enzima de inhibicion (elisa) para deteccion y cuantificacion de anticuerpos en muestras biologicas
Barrieux et al. Nonidentity of the 48,000-dalton protein of mRNA-protein particles and the beta subunit of eukaryotic initiation factor 2.
Perpetuo et al. Development of an operational synaptobrevin‐based fluorescent substrate for tetanus neurotoxin quantification
Smales et al. Purification and characterization of lysozyme‐pregnanediol glucuronide conjugates: the effect of the hapten and coupling reagent on the substitution level, sites of acylation and the consequences for the development of future immunoassays
DE60029570D1 (de) Verfahren zur isolierung der cd8+-zellen, und entsprechende hybridomazellen, antikörper und polypeptide
Klugerman CHEMICAL AND PHYSICAL VARIABLES AFFECTING FLUORESCEIN ISOTHIOCYANATE AND ITS PROTEIN CONJUGATES
BRPI9715268B8 (pt) preparações farmacêuticas liofilizadas estáveis de anticorpos monoclonais ou policlonais, bem como processo para sua produção
Kakizaki et al. A sandwich enzyme immunoassay for human pancreatic elastase III